Free Trial

Adaptive Biotechnologies (ADPT) Financials

Adaptive Biotechnologies logo
$7.74 -0.08 (-1.02%)
Closing price 04/15/2025 04:00 PM Eastern
Extended Trading
$7.72 -0.02 (-0.19%)
As of 04/15/2025 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Adaptive Biotechnologies

Annual Income Statements for Adaptive Biotechnologies

This table shows Adaptive Biotechnologies' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
-43 -46 -70 -146 -207 -200 -225 -159
Consolidated Net Income / (Loss)
-43 -46 -69 -146 -207 -200 -225 -160
Net Income / (Loss) Continuing Operations
-43 -46 -69 -146 -207 -200 -225 -160
Total Pre-Tax Income
-43 -46 -69 -146 -207 -200 -225 -160
Total Operating Income
-44 -50 -78 -153 -209 -200 -227 -163
Total Gross Profit
0.01 36 63 76 105 127 95 107
Total Revenue
16 56 85 98 154 185 170 179
Operating Revenue
16 56 85 98 154 185 170 179
Total Cost of Revenue
16 20 22 23 49 58 76 72
Operating Cost of Revenue
16 20 22 23 49 58 76 72
Total Operating Expenses
44 86 141 229 314 328 322 269
Selling, General & Admin Expense
16 20 30 50 75 89 84 73
Marketing Expense
17 24 38 61 95 96 89 85
Research & Development Expense
32 39 71 116 142 142 122 103
Amortization Expense
1.69 1.70 1.70 1.70 1.70 1.70 1.70 1.70
Impairment Charge
- - - - 0.00 0.00 25 7.21
Total Other Income / (Expense), net
1.64 3.31 9.79 6.59 1.67 -0.18 1.73 2.95
Interest Expense
- - - 0.00 0.00 4.24 14 12
Interest & Investment Income
1.64 3.31 9.79 6.59 1.67 4.06 16 15
Net Income / (Loss) Attributable to Noncontrolling Interest
- - 0.00 0.00 -0.02 -0.18 -0.05 -0.10
Basic Earnings per Share
($3.50) ($3.67) ($1.01) ($1.11) ($1.48) ($1.40) ($1.56) ($1.08)
Weighted Average Basic Shares Outstanding
12.20M 12.63M 69.17M 131.22M 140.35M 142.52M 144.38M 147.10M
Diluted Earnings per Share
($3.50) ($3.67) ($1.01) ($1.11) ($1.48) ($1.40) ($1.56) ($1.08)
Weighted Average Diluted Shares Outstanding
12.20M 12.63M 69.17M 131.22M 140.35M 142.52M 144.38M 147.10M
Weighted Average Basic & Diluted Shares Outstanding
12.20M 12.63M 69.17M 131.22M 140.35M 143.23M 145.09M 148.58M

Quarterly Income Statements for Adaptive Biotechnologies

This table shows Adaptive Biotechnologies' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
-45 -40 -58 -48 -50 -69 -48 -46 -32 -34
Consolidated Net Income / (Loss)
-45 -40 -58 -48 -50 -69 -48 -46 -32 -34
Net Income / (Loss) Continuing Operations
-45 -40 -58 -48 -50 -69 -48 -46 -32 -34
Total Pre-Tax Income
-45 -40 -58 -48 -50 -69 -48 -46 -32 -34
Total Operating Income
-45 -39 -57 -48 -51 -71 -49 -47 -33 -34
Total Gross Profit
33 39 19 31 19 26 24 24 30 29
Total Revenue
48 55 38 49 38 46 42 43 46 47
Operating Revenue
48 55 38 49 38 46 42 43 46 47
Total Cost of Revenue
15 17 19 18 19 20 18 19 17 18
Operating Cost of Revenue
15 17 19 18 19 20 18 19 17 18
Total Operating Expenses
78 78 76 79 70 97 73 71 62 63
Selling, General & Admin Expense
21 22 21 22 20 21 20 18 17 18
Marketing Expense
22 24 22 24 20 22 22 20 21 22
Research & Development Expense
36 31 33 32 29 29 30 25 24 23
Amortization Expense
0.43 0.43 0.42 0.42 0.43 0.43 0.42 0.42 0.43 0.43
Total Other Income / (Expense), net
0.11 -0.98 -0.51 0.01 0.63 1.60 1.23 1.07 0.54 0.12
Interest Expense
0.65 3.59 3.53 3.61 3.65 3.01 2.99 2.70 2.94 2.95
Interest & Investment Income
0.77 2.60 3.02 3.61 4.28 4.61 4.22 3.77 3.47 3.07
Net Income / (Loss) Attributable to Noncontrolling Interest
-0.04 -0.04 -0.00 -0.00 -0.03 -0.03 -0.03 -0.03 -0.03 -0.03
Basic Earnings per Share
($0.32) ($0.27) ($0.40) ($0.33) ($0.35) ($0.48) ($0.33) ($0.31) ($0.22) ($0.22)
Weighted Average Basic Shares Outstanding
142.93M 142.52M 143.51M 144.40M 144.70M 144.38M 145.79M 147.41M 147.52M 147.10M
Diluted Earnings per Share
($0.32) ($0.27) ($0.40) ($0.33) ($0.35) ($0.48) ($0.33) ($0.31) ($0.22) ($0.22)
Weighted Average Diluted Shares Outstanding
142.93M 142.52M 143.51M 144.40M 144.70M 144.38M 145.79M 147.41M 147.52M 147.10M
Weighted Average Basic & Diluted Shares Outstanding
143.01M 143.23M 144.31M 144.65M 144.77M 145.09M 147.37M 147.47M 147.58M 148.58M

Annual Cash Flow Statements for Adaptive Biotechnologies

This table details how cash moves in and out of Adaptive Biotechnologies' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents
52 -30 44 27 16 -49 -24 -17
Net Cash From Operating Activities
-35 -32 205 -150 -193 -184 -156 -95
Net Cash From Continuing Operating Activities
-35 -32 205 -150 -193 -184 -156 -95
Net Income / (Loss) Continuing Operations
-43 -46 -69 -146 -207 -200 -225 -160
Consolidated Net Income / (Loss)
-43 -46 -69 -146 -207 -200 -225 -160
Depreciation Expense
4.10 4.30 6.09 6.77 12 19 21 18
Amortization Expense
2.04 0.49 -2.77 2.48 8.93 2.44 -7.49 -6.51
Non-Cash Adjustments To Reconcile Net Income
7.31 11 16 28 50 66 102 71
Changes in Operating Assets and Liabilities, net
-5.48 -1.72 255 -41 -57 -72 -46 -17
Net Cash From Investing Activities
36 0.74 -482 -117 181 2.91 130 78
Net Cash From Continuing Investing Activities
36 0.74 -482 -117 181 2.91 130 78
Purchase of Property, Plant & Equipment
-2.42 -6.30 -11 -19 -62 -16 -11 -3.66
Purchase of Investments
-125 -147 -884 -695 -317 -279 -430 -244
Sale and/or Maturity of Investments
164 154 414 597 560 298 570 326
Net Cash From Financing Activities
50 1.25 320 294 27 132 2.25 0.24
Net Cash From Continuing Financing Activities
50 1.25 320 294 27 132 2.25 0.24
Repurchase of Common Equity
0.00 0.00 -4.99 -0.32 0.00 0.00 0.00 0.00
Issuance of Common Equity
0.00 0.00 321 272 0.00 0.00 0.00 0.00
Other Financing Activities, net
0.22 1.27 4.06 22 27 132 2.25 0.24
Cash Interest Paid
- - - 0.00 0.00 0.49 8.99 8.86

Quarterly Cash Flow Statements for Adaptive Biotechnologies

This table details how cash moves in and out of Adaptive Biotechnologies' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
141 -128 4.50 15 -21 -24 6.20 -11 -22 9.76
Net Cash From Operating Activities
-42 -30 -59 -24 -47 -27 -38 -17 -27 -12
Net Cash From Continuing Operating Activities
-42 -30 -59 -24 -47 -27 -38 -17 -27 -12
Net Income / (Loss) Continuing Operations
-45 -40 -58 -48 -50 -69 -48 -46 -32 -34
Consolidated Net Income / (Loss)
-45 -40 -58 -48 -50 -69 -48 -46 -32 -34
Depreciation Expense
4.96 4.86 5.00 5.23 5.34 4.96 4.79 4.58 4.16 4.02
Amortization Expense
0.84 -0.66 -1.19 -1.50 -2.27 -2.53 -2.22 -1.68 -1.58 -1.03
Non-Cash Adjustments To Reconcile Net Income
16 16 19 20 19 44 17 23 15 15
Changes in Operating Assets and Liabilities, net
-19 -10 -24 0.45 -19 -3.51 -10 2.83 -13 3.05
Net Cash From Investing Activities
58 -98 63 37 26 3.21 45 5.88 5.29 22
Net Cash From Continuing Investing Activities
58 -98 63 37 26 3.21 45 5.88 5.29 22
Purchase of Property, Plant & Equipment
-5.43 -2.54 -2.92 -3.70 -2.78 -1.30 -1.51 -1.73 -0.34 -0.08
Purchase of Investments
-29 -165 -89 -99 -119 -122 -53 -83 -63 -45
Sale and/or Maturity of Investments
92 70 155 140 148 127 100 90 69 67
Net Cash From Financing Activities
126 0.01 0.67 1.47 0.02 0.09 0.04 0.03 0.04 0.13
Net Cash From Continuing Financing Activities
126 0.01 0.67 1.47 0.02 0.09 0.04 0.03 0.04 0.13
Other Financing Activities, net
0.83 125 0.67 1.47 0.02 0.09 0.04 0.03 0.04 0.13
Cash Interest Paid
- 0.49 2.76 1.88 2.45 1.90 2.29 2.09 2.16 2.32

Annual Balance Sheets for Adaptive Biotechnologies

This table presents Adaptive Biotechnologies' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Total Assets
333 912 1,116 923 857 661 539
Total Current Assets
181 613 727 403 562 410 284
Cash & Equivalents
55 97 123 139 90 65 48
Short-Term Investments
110 480 565 214 408 281 174
Accounts Receivable
4.81 13 10 17 40 38 42
Inventories, net
7.84 9.07 14 19 14 14 8.44
Prepaid Expenses
3.06 14 15 13 9.44 11 11
Plant, Property, & Equipment, net
19 60 40 85 83 68 49
Total Noncurrent Assets
133 239 350 435 211 183 207
Long-Term Investments
0.00 105 119 217 - 0.00 34
Goodwill
119 119 119 119 119 119 119
Intangible Assets
14 12 10 8.53 6.83 5.13 3.43
Other Noncurrent Operating Assets
0.25 2.92 102 91 85 59 51
Total Liabilities & Shareholders' Equity
333 912 1,116 923 857 661 539
Total Liabilities
30 341 373 319 393 353 337
Total Current Liabilities
23 78 105 114 110 88 98
Short-Term Debt
- - - - - 0.00 0.87
Accounts Payable
1.79 4.45 3.24 3.31 8.08 7.72 7.27
Accrued Expenses
2.56 4.37 13 9.34 12 8.60 8.16
Current Deferred Revenue
14 61 73 80 64 49 56
Current Employee Benefit Liabilities
4.64 8.12 12 16 16 14 16
Other Current Liabilities
- 0.00 3.53 5.06 9.23 9.38 10
Total Noncurrent Liabilities
7.14 263 268 205 283 265 239
Long-Term Debt
- - - - 125 131 132
Noncurrent Deferred Revenue
6.81 226 164 99 59 45 27
Other Noncurrent Operating Liabilities
0.34 37 104 107 99 89 79
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-258 571 743 604 464 308 202
Total Preferred & Common Equity
-258 571 743 604 464 308 203
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-258 571 743 604 464 308 203
Common Stock
38 936 1,254 1,324 1,387 1,453 1,506
Retained Earnings
-296 -365 -512 -719 -919 -1,144 -1,304
Accumulated Other Comprehensive Income / (Loss)
-0.11 0.67 0.89 -1.14 -4.12 0.22 0.17
Noncontrolling Interest
- - 0.00 0.11 -0.07 -0.12 -0.22

Quarterly Balance Sheets for Adaptive Biotechnologies

This table presents Adaptive Biotechnologies' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
884 791 765 718 620 585 559
Total Current Assets
564 501 477 435 374 352 308
Cash & Equivalents
218 95 109 89 71 60 38
Short-Term Investments
291 346 308 282 238 232 205
Accounts Receivable
27 31 32 31 42 36 41
Inventories, net
17 20 19 19 13 13 12
Prepaid Expenses
12 9.79 9.07 13 9.85 11 12
Plant, Property, & Equipment, net
87 81 79 77 65 55 51
Total Noncurrent Assets
233 209 208 206 178 178 199
Long-Term Investments
20 - - - - - 24
Goodwill
119 119 119 119 119 119 119
Intangible Assets
7.26 6.41 5.99 5.56 4.71 4.28 3.85
Other Noncurrent Operating Assets
87 83 83 81 54 55 52
Total Liabilities & Shareholders' Equity
884 791 765 718 620 585 559
Total Liabilities
396 368 369 356 346 343 335
Total Current Liabilities
104 90 95 93 83 88 88
Accounts Payable
4.16 6.33 9.16 4.48 12 9.87 7.35
Accrued Expenses
11 8.04 8.36 10 7.91 6.71 6.06
Current Deferred Revenue
68 60 58 55 47 52 52
Current Employee Benefit Liabilities
13 6.12 11 11 6.40 9.52 12
Other Current Liabilities
8.53 9.29 9.35 9.48 9.59 9.81 10
Total Noncurrent Liabilities
292 277 273 263 263 255 247
Long-Term Debt
- - - 127 132 132 133
Noncurrent Deferred Revenue
67 54 51 44 44 39 33
Other Noncurrent Operating Liabilities
225 224 222 92 87 84 82
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
488 424 396 362 275 241 224
Total Preferred & Common Equity
488 424 396 362 275 242 224
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
488 424 396 362 275 242 224
Common Stock
1,373 1,403 1,422 1,437 1,467 1,480 1,493
Retained Earnings
-879 -977 -1,025 -1,075 -1,192 -1,238 -1,270
Accumulated Other Comprehensive Income / (Loss)
-5.97 -1.91 -0.89 -0.25 -0.11 -0.18 0.50
Noncontrolling Interest
-0.03 -0.07 -0.07 -0.10 -0.15 -0.17 -0.20

Annual Metrics and Ratios for Adaptive Biotechnologies

This table displays calculated financial ratios and metrics derived from Adaptive Biotechnologies' official financial filings.

Metric 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics
- - - - - - - -
Revenue Growth
0.00% 254.79% 52.83% 15.65% 56.88% 20.06% -8.11% 5.10%
EBITDA Growth
0.00% -134.60% 16.54% -91.27% -30.79% 4.93% -19.86% 29.20%
EBIT Growth
0.00% -123.75% -57.55% 2.53% -36.74% 4.20% -13.41% 28.40%
NOPAT Growth
0.00% -123.75% 21.22% -94.94% -36.74% 4.20% -13.41% 28.40%
Net Income Growth
0.00% -8.44% -47.71% -113.14% -41.76% 3.34% -12.45% 29.16%
EPS Growth
0.00% -4.86% 72.48% -9.90% -33.33% 5.41% -11.43% 30.77%
Operating Cash Flow Growth
0.00% 7.46% 736.73% -172.87% -28.76% 4.56% 15.02% 39.09%
Free Cash Flow Firm Growth
0.00% 0.00% 196.15% -146.62% -57.52% 18.96% 18.88% 36.92%
Invested Capital Growth
0.00% 0.00% -140.39% 42.90% 153.36% 169.24% 1.40% -13.75%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 107.05% -24.10% 10.28% -5.24% 0.94%
EBITDA Q/Q Growth
0.00% 0.00% 0.00% -13.96% -8.58% 10.29% -18.66% 19.96%
EBIT Q/Q Growth
0.00% 0.00% 0.00% -15.10% -9.06% 10.07% -16.34% 18.64%
NOPAT Q/Q Growth
0.00% 0.00% 0.00% -15.10% -9.06% 10.07% -16.34% 18.64%
Net Income Q/Q Growth
0.00% 0.00% 0.00% 8.03% -34.79% 9.56% -14.95% 18.30%
EPS Q/Q Growth
0.00% 0.00% 0.00% -211.00% -8.03% 10.83% -15.56% 19.40%
Operating Cash Flow Q/Q Growth
0.00% 0.00% -9.43% -9.55% -7.82% 11.46% 1.94% 13.17%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 0.00% -6.07% -104.17% 46.06% 6.86%
Invested Capital Q/Q Growth
0.00% 0.00% 0.00% 16.96% 77.24% 328.37% -23.16% -10.41%
Profitability Metrics
- - - - - - - -
Gross Margin
0.06% 64.67% 73.82% 77.10% 68.06% 68.75% 55.63% 59.72%
EBITDA Margin
-244.36% -80.79% -88.24% -145.93% -121.66% -96.34% -125.67% -84.66%
Operating Margin
-283.48% -89.39% -92.15% -155.33% -135.39% -108.03% -133.33% -90.83%
EBIT Margin
-283.48% -89.39% -92.15% -155.33% -135.39% -108.03% -133.33% -90.83%
Profit (Net Income) Margin
-273.00% -83.44% -80.65% -148.63% -134.31% -108.13% -132.32% -89.18%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
96.30% 93.35% 87.52% 95.69% 99.20% 100.09% 99.24% 98.18%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% -50.58% -66.84% 0.00% 0.00% -223.93% -172.93% -132.04%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% -72.99% -128.25% 0.00% 0.00% -211.15% -150.38% -104.97%
Return on Net Nonoperating Assets (RNNOA)
0.00% 19.89% 187.16% 0.00% 0.00% 186.41% 114.59% 69.55%
Return on Equity (ROE)
0.00% -30.68% 7.46% -22.25% -30.77% -37.52% -58.34% -62.49%
Cash Return on Invested Capital (CROIC)
0.00% -1,002.31% 0.00% 0.00% -718.96% -315.60% -174.32% -117.27%
Operating Return on Assets (OROA)
0.00% -29.91% -12.59% -15.07% -20.49% -22.49% -29.92% -27.08%
Return on Assets (ROA)
0.00% -13.96% -22.04% -14.42% -20.33% -22.51% -29.69% -26.59%
Return on Common Equity (ROCE)
0.00% 26.16% 8.89% -22.25% -30.77% -37.51% -58.35% -62.54%
Return on Equity Simple (ROE_SIMPLE)
0.00% 17.99% -12.01% -19.67% -34.32% -43.17% -73.06% -78.73%
Net Operating Profit after Tax (NOPAT)
-31 -70 -55 -107 -146 -140 -159 -114
NOPAT Margin
-198.44% -62.57% -64.50% -108.73% -94.77% -75.62% -93.33% -63.58%
Net Nonoperating Expense Percent (NNEP)
0.00% -12.08% -2.71% -5.27% -8.86% -12.78% -22.56% -27.07%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - -23.77% -36.21% -33.89%
Cost of Revenue to Revenue
99.94% 35.33% 26.18% 22.90% 31.94% 31.25% 44.37% 40.28%
SG&A Expenses to Revenue
101.66% 36.67% 35.65% 50.35% 48.27% 47.77% 49.29% 40.68%
R&D to Revenue
203.93% 70.35% 83.11% 117.98% 92.22% 76.50% 71.72% 57.53%
Operating Expenses to Revenue
283.54% 154.05% 165.96% 232.43% 203.45% 176.78% 188.96% 150.55%
Earnings before Interest and Taxes (EBIT)
-44 -100 -157 -153 -209 -200 -227 -163
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-38 -90 -75 -144 -188 -179 -214 -152
Valuation Ratios
- - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 6.51 10.88 6.56 2.35 2.30 4.36
Price to Tangible Book Value (P/TBV)
0.00 0.00 8.45 13.17 8.31 3.23 3.85 11.02
Price to Revenue (P/Rev)
19.12 5.39 43.73 82.20 25.66 5.90 4.17 4.94
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 5.05 0.00 0.00 100.01 7.89 5.33 9.55
Enterprise Value to Revenue (EV/Rev)
0.00 12.50 35.71 74.00 21.96 3.88 2.90 4.26
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 14.79 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 9.15 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.27 0.42 0.66
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.27 0.42 0.65
Financial Leverage
0.00 -0.55 -1.16 -1.13 -1.02 -0.88 -0.76 -0.66
Leverage Ratio
0.00 1.10 1.42 1.54 1.51 1.67 1.97 2.35
Compound Leverage Factor
0.00 1.03 1.25 1.48 1.50 1.67 1.95 2.31
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 21.27% 29.77% 39.69%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.26%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 21.27% 29.77% 39.44%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 370.51% 0.00% 0.00% 0.02% -0.01% -0.03% -0.07%
Common Equity to Total Capital
0.00% -85.26% 200.00% 100.00% 99.98% 78.74% 70.26% 60.37%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 -0.70 -0.61 -0.88
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 2.09 1.01 0.81
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 -0.70 -0.61 -0.87
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 -0.89 -0.82 -1.17
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 2.66 1.36 1.08
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 -0.89 -0.82 -1.16
Altman Z-Score
0.00 5.01 10.08 12.67 6.15 0.25 -1.51 -2.06
Noncontrolling Interest Sharing Ratio
0.00% 185.26% 64.19% 0.00% 0.01% 0.00% -0.02% -0.07%
Liquidity Ratios
- - - - - - - -
Current Ratio
0.00 15.85 7.82 6.91 3.54 5.12 4.66 2.89
Quick Ratio
0.00 14.90 7.53 6.64 3.26 4.90 4.37 2.69
Cash Flow Metrics
- - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -345 332 -155 -244 -197 -160 -101
Operating Cash Flow to CapEx
-1,574.44% -1,024.26% 1,833.96% -796.06% -312.13% -1,125.11% -1,461.38% -2,598.58%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 -46.60 -11.61 -8.73
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 -43.40 -11.33 -8.22
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 -47.26 -12.10 -8.54
Efficiency Ratios
- - - - - - - -
Asset Turnover
0.00 0.17 0.14 0.10 0.15 0.21 0.22 0.30
Accounts Receivable Turnover
0.00 11.58 9.73 8.66 11.24 6.45 4.36 4.49
Inventory Turnover
0.00 2.51 2.63 1.95 2.96 3.44 5.23 6.30
Fixed Asset Turnover
0.00 2.91 2.14 1.97 2.47 2.20 2.25 3.06
Accounts Payable Turnover
0.00 10.97 7.13 5.86 15.07 10.17 9.56 9.62
Days Sales Outstanding (DSO)
0.00 31.52 37.51 42.15 32.46 56.60 83.63 81.28
Days Inventory Outstanding (DIO)
0.00 145.46 138.53 187.38 123.36 106.26 69.81 57.95
Days Payable Outstanding (DPO)
0.00 33.27 51.18 62.29 24.22 35.90 38.17 37.94
Cash Conversion Cycle (CCC)
0.00 143.70 124.86 167.24 131.60 126.95 115.27 101.29
Capital & Investment Metrics
- - - - - - - -
Invested Capital
0.00 275 -111 -64 34 91 93 80
Invested Capital Turnover
0.00 0.81 1.04 -1.13 -10.42 2.96 1.85 2.08
Increase / (Decrease) in Invested Capital
0.00 275 -387 48 97 57 1.28 -13
Enterprise Value (EV)
0.00 696 3,038 7,281 3,390 720 494 762
Market Capitalization
300 300 3,720 8,087 3,960 1,093 709 885
Book Value per Share
$0.00 ($20.44) $4.59 $5.43 $4.28 $3.25 $2.13 $1.37
Tangible Book Value per Share
$0.00 ($61.87) $3.54 $4.49 $3.38 $2.37 $1.27 $0.54
Total Capital
0.00 605 571 743 604 589 439 336
Total Debt
0.00 0.00 0.00 0.00 0.00 125 131 133
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 125 131 132
Net Debt
0.00 -330 -682 -807 -570 -373 -216 -123
Capital Expenditures (CapEx)
2.21 13 11 19 62 16 11 3.66
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 -14 -42 -67 -64 -46 -24 -36
Debt-free Net Working Capital (DFNWC)
0.00 158 534 622 289 452 322 187
Net Working Capital (NWC)
0.00 316 534 622 289 452 322 186
Net Nonoperating Expense (NNE)
12 23 14 39 61 60 66 46
Net Nonoperating Obligations (NNO)
0.00 -330 -682 -807 -570 -373 -216 -123
Total Depreciation and Amortization (D&A)
6.14 9.57 3.33 9.25 21 22 13 11
Debt-free, Cash-free Net Working Capital to Revenue
0.00% -25.51% -49.95% -67.65% -41.54% -24.74% -14.23% -19.97%
Debt-free Net Working Capital to Revenue
0.00% 283.70% 628.15% 631.94% 187.21% 244.11% 189.21% 104.25%
Net Working Capital to Revenue
0.00% 283.70% 1,914.20% 631.94% 187.21% 244.11% 189.21% 103.77%
Earnings Adjustments
- - - - - - - -
Adjusted Basic Earnings per Share
($3.50) ($3.67) ($1.01) ($1.11) ($1.48) ($1.40) ($1.56) ($1.08)
Adjusted Weighted Average Basic Shares Outstanding
12.20M 12.63M 126.32M 139.22M 141.58M 142.52M 144.38M 147.10M
Adjusted Diluted Earnings per Share
($3.50) ($3.67) ($1.01) ($1.11) ($1.48) ($1.40) ($1.56) ($1.08)
Adjusted Weighted Average Diluted Shares Outstanding
12.20M 12.63M 126.32M 139.22M 141.58M 142.52M 144.38M 147.10M
Adjusted Basic & Diluted Earnings per Share
($3.50) ($3.67) ($1.01) ($1.11) ($1.48) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
12.20M 12.63M 69.17M 131.22M 140.35M 143.23M 145.09M 148.58M
Normalized Net Operating Profit after Tax (NOPAT)
-31 -70 -55 -107 -146 -140 -141 -109
Normalized NOPAT Margin
-194.69% -62.57% -64.50% -108.73% -94.77% -75.62% -82.88% -60.76%
Pre Tax Income Margin
-273.00% -83.44% -80.65% -148.63% -134.31% -108.13% -132.32% -89.18%
Debt Service Ratios
- - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 -47.24 -16.45 -14.04
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 -33.07 -11.52 -9.83
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 -51.09 -17.23 -14.35
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 -36.92 -12.29 -10.14
Payout Ratios
- - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% -14.54% -0.22% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Adaptive Biotechnologies

This table displays calculated financial ratios and metrics derived from Adaptive Biotechnologies' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
21.19% 45.53% -2.52% 12.06% -20.72% -17.06% 11.23% -11.72% 22.46% 3.66%
EBITDA Growth
22.30% 36.93% 6.60% 5.71% -20.82% -96.19% 13.47% -0.75% 37.26% 55.06%
EBIT Growth
19.34% 36.38% 9.31% 8.92% -12.16% -81.36% 14.74% 1.05% 35.96% 52.39%
NOPAT Growth
19.34% 36.38% 9.31% 8.92% -12.16% -81.36% 14.74% 1.05% 35.96% 52.39%
Net Income Growth
19.07% 34.53% 8.12% 8.20% -11.05% -72.94% 17.62% 3.27% 36.22% 51.46%
EPS Growth
20.00% 38.64% 9.09% 10.81% -9.38% -77.78% 17.50% 6.06% 37.14% 54.17%
Operating Cash Flow Growth
2.38% 44.23% 8.22% 49.95% -10.08% 10.28% 35.16% 26.55% 42.03% 53.62%
Free Cash Flow Firm Growth
120.20% 39.66% 125.26% 155.09% -818.56% 39.83% -594.78% -345.34% 104.34% 78.52%
Invested Capital Growth
-308.97% 169.24% -131.84% -131.43% 401.35% 1.40% 661.72% 483.92% -26.03% -13.75%
Revenue Q/Q Growth
9.55% 15.40% -31.80% 29.96% -22.50% 20.74% -8.54% 3.15% 7.51% 2.21%
EBITDA Q/Q Growth
15.22% 11.74% -52.58% 17.42% -8.64% -43.32% 32.70% 3.85% 32.34% -2.66%
EBIT Q/Q Growth
13.47% 13.75% -45.95% 16.39% -6.56% -39.47% 31.39% 2.96% 31.04% -3.69%
NOPAT Q/Q Growth
13.47% 13.75% -45.95% 16.39% -6.56% -39.47% 31.39% 2.96% 31.04% -3.69%
Net Income Q/Q Growth
12.99% 11.36% -43.64% 17.14% -5.26% -38.03% 31.57% 2.70% 30.60% -5.05%
EPS Q/Q Growth
13.51% 15.63% -48.15% 17.50% -6.06% -37.14% 31.25% 6.06% 29.03% 0.00%
Operating Cash Flow Q/Q Growth
9.89% 29.21% -97.05% 60.18% -98.18% 42.31% -42.41% 54.88% -56.42% 53.85%
Free Cash Flow Firm Q/Q Growth
127.11% -410.78% 134.54% 89.28% -453.64% 73.98% -184.04% 6.15% 106.25% -228.83%
Invested Capital Q/Q Growth
-159.07% 328.37% -118.35% -27.00% 666.37% -23.16% 1.63% -13.20% 9.12% -10.41%
Profitability Metrics
- - - - - - - - - -
Gross Margin
68.83% 69.95% 50.38% 63.39% 48.98% 57.16% 56.89% 55.27% 64.11% 61.98%
EBITDA Margin
-82.87% -63.38% -141.79% -90.10% -126.30% -149.91% -110.31% -102.83% -64.71% -65.00%
Operating Margin
-94.98% -70.99% -151.92% -97.74% -134.38% -155.22% -116.45% -109.56% -70.27% -71.30%
EBIT Margin
-94.98% -70.99% -151.92% -97.74% -134.38% -155.22% -116.45% -109.56% -70.27% -71.30%
Profit (Net Income) Margin
-94.75% -72.77% -153.27% -97.72% -132.72% -151.73% -113.52% -107.08% -69.12% -71.04%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
99.75% 102.51% 100.89% 99.99% 98.76% 97.75% 97.48% 97.74% 98.36% 99.65%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% -147.15% -1,093.91% -559.27% -420.13% -201.33% -368.01% -428.79% -83.25% -103.64%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% -144.45% -1,090.15% -555.97% -416.32% -194.62% -363.70% -424.24% -78.33% -97.72%
Return on Net Nonoperating Assets (RNNOA)
0.00% 127.53% 1,050.17% 527.76% 376.88% 148.31% 323.46% 384.06% 50.28% 64.74%
Return on Equity (ROE)
-38.89% -19.63% -43.74% -31.51% -43.25% -53.01% -44.55% -44.73% -32.97% -38.90%
Cash Return on Invested Capital (CROIC)
0.00% -315.60% 0.00% 0.00% -246.62% -174.32% -280.51% -313.07% -103.57% -117.27%
Operating Return on Assets (OROA)
-17.01% -14.78% -33.95% -23.59% -30.15% -34.83% -28.79% -27.40% -19.52% -21.26%
Return on Assets (ROA)
-16.97% -15.15% -34.25% -23.58% -29.78% -34.04% -28.06% -26.78% -19.20% -21.18%
Return on Common Equity (ROCE)
-38.89% -19.63% -43.74% -31.51% -43.25% -53.03% -44.57% -44.75% -32.98% -38.93%
Return on Equity Simple (ROE_SIMPLE)
-45.42% 0.00% -46.05% -48.23% -54.19% 0.00% -78.26% -88.40% -87.30% 0.00%
Net Operating Profit after Tax (NOPAT)
-32 -27 -40 -33 -36 -50 -34 -33 -23 -24
NOPAT Margin
-66.49% -49.69% -106.34% -68.41% -94.07% -108.66% -81.52% -76.69% -49.19% -49.91%
Net Nonoperating Expense Percent (NNEP)
-2.33% -2.70% -3.75% -3.30% -3.81% -6.70% -4.31% -4.55% -4.93% -5.93%
Return On Investment Capital (ROIC_SIMPLE)
- -4.65% - - - -11.33% - - - -7.05%
Cost of Revenue to Revenue
31.17% 30.05% 49.62% 36.61% 51.02% 42.84% 43.11% 44.73% 35.89% 38.02%
SG&A Expenses to Revenue
43.39% 40.63% 55.33% 45.58% 52.94% 45.27% 46.80% 41.43% 37.17% 38.05%
R&D to Revenue
74.55% 56.56% 86.60% 65.89% 75.25% 62.79% 72.23% 58.70% 52.04% 48.87%
Operating Expenses to Revenue
163.82% 140.94% 202.30% 161.13% 183.36% 212.38% 173.34% 164.83% 134.38% 133.28%
Earnings before Interest and Taxes (EBIT)
-45 -39 -57 -48 -51 -71 -49 -47 -33 -34
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-40 -35 -53 -44 -48 -69 -46 -44 -30 -31
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
2.09 2.35 2.98 2.45 2.18 2.30 1.69 2.21 3.37 4.36
Price to Tangible Book Value (P/TBV)
2.81 3.23 4.23 3.57 3.32 3.85 3.08 4.51 7.48 11.02
Price to Revenue (P/Rev)
6.05 5.90 6.86 5.11 4.39 4.17 2.67 3.16 4.26 4.94
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 7.89 0.00 0.00 4.54 5.33 3.07 4.58 6.96 9.55
Enterprise Value to Revenue (EV/Rev)
2.91 3.88 4.47 2.91 3.04 2.90 1.65 2.21 3.50 4.26
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.00 0.27 0.00 0.00 0.36 0.42 0.48 0.55 0.59 0.66
Long-Term Debt to Equity
0.00 0.27 0.00 0.00 0.35 0.42 0.48 0.55 0.59 0.65
Financial Leverage
-1.02 -0.88 -0.96 -0.95 -0.91 -0.76 -0.89 -0.91 -0.64 -0.66
Leverage Ratio
1.65 1.67 1.69 1.72 1.89 1.97 2.02 2.12 2.18 2.35
Compound Leverage Factor
1.64 1.71 1.70 1.72 1.86 1.92 1.97 2.07 2.15 2.34
Debt to Total Capital
0.00% 21.27% 0.00% 0.00% 26.43% 29.77% 32.38% 35.36% 37.25% 39.69%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.65% 0.00% 0.00% 0.00% 0.00% 0.26%
Long-Term Debt to Total Capital
0.00% 21.27% 0.00% 0.00% 25.78% 29.77% 32.38% 35.36% 37.25% 39.44%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
-0.01% -0.01% -0.02% -0.02% -0.02% -0.03% -0.04% -0.05% -0.06% -0.07%
Common Equity to Total Capital
100.01% 78.74% 100.02% 100.02% 73.59% 70.26% 67.66% 64.68% 62.81% 60.37%
Debt to EBITDA
0.00 -0.70 0.00 0.00 -0.72 -0.61 -0.64 -0.64 -0.70 -0.88
Net Debt to EBITDA
0.00 2.09 0.00 0.00 1.34 1.01 0.86 0.77 0.71 0.81
Long-Term Debt to EBITDA
0.00 -0.70 0.00 0.00 -0.70 -0.61 -0.64 -0.64 -0.70 -0.87
Debt to NOPAT
0.00 -0.89 0.00 0.00 -0.95 -0.82 -0.86 -0.87 -0.95 -1.17
Net Debt to NOPAT
0.00 2.66 0.00 0.00 1.77 1.36 1.16 1.05 0.96 1.08
Long-Term Debt to NOPAT
0.00 -0.89 0.00 0.00 -0.93 -0.82 -0.86 -0.87 -0.95 -1.16
Altman Z-Score
0.79 0.87 0.95 0.34 -0.18 -0.73 -1.30 -1.47 -1.23 -1.27
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% -0.01% -0.01% -0.02% -0.03% -0.04% -0.05% -0.07%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
5.43 5.12 5.56 5.00 4.67 4.66 4.51 3.99 3.52 2.89
Quick Ratio
5.14 4.90 5.23 4.71 4.31 4.37 4.23 3.72 3.24 2.69
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
27 -85 29 55 -196 -51 -145 -136 8.51 -11
Operating Cash Flow to CapEx
-780.71% -1,180.92% -2,022.98% -637.17% -1,680.49% -2,074.88% -2,538.25% -1,000.75% -7,867.73% -15,613.75%
Free Cash Flow to Firm to Interest Expense
41.78 -23.65 8.30 15.38 -53.69 -16.94 -48.42 -50.45 2.89 -3.71
Operating Cash Flow to Interest Expense
-64.94 -8.37 -16.75 -6.53 -12.78 -8.94 -12.81 -6.42 -9.21 -4.23
Operating Cash Flow Less CapEx to Interest Expense
-73.26 -9.08 -17.58 -7.56 -13.54 -9.37 -13.32 -7.06 -9.33 -4.26
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.18 0.21 0.22 0.24 0.22 0.22 0.25 0.25 0.28 0.30
Accounts Receivable Turnover
7.70 6.45 6.89 6.86 6.22 4.36 4.78 5.03 4.92 4.49
Inventory Turnover
3.13 3.44 3.10 3.61 3.94 5.23 4.52 4.74 4.68 6.30
Fixed Asset Turnover
1.93 2.20 2.20 2.28 2.20 2.25 2.38 2.50 2.77 3.06
Accounts Payable Turnover
8.97 10.17 10.32 11.46 16.78 9.56 8.10 8.02 12.45 9.62
Days Sales Outstanding (DSO)
47.43 56.60 52.96 53.19 58.66 83.63 76.34 72.62 74.14 81.28
Days Inventory Outstanding (DIO)
116.61 106.26 117.67 101.15 92.69 69.81 80.78 76.93 77.92 57.95
Days Payable Outstanding (DPO)
40.70 35.90 35.38 31.85 21.76 38.17 45.07 45.50 29.32 37.94
Cash Conversion Cycle (CCC)
123.35 126.95 135.24 122.49 129.60 115.27 112.05 104.05 122.74 101.29
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
-40 91 -17 -21 120 93 94 82 89 80
Invested Capital Turnover
-16.13 2.96 10.29 8.17 4.47 1.85 4.51 5.59 1.69 2.08
Increase / (Decrease) in Invested Capital
-59 57 -69 -89 160 1.28 111 103 -31 -13
Enterprise Value (EV)
489 720 824 551 547 494 288 374 620 762
Market Capitalization
1,017 1,093 1,265 968 788 709 466 533 755 885
Book Value per Share
$3.41 $3.25 $2.96 $2.74 $2.50 $2.13 $1.89 $1.64 $1.52 $1.37
Tangible Book Value per Share
$2.53 $2.37 $2.09 $1.88 $1.64 $1.27 $1.04 $0.80 $0.68 $0.54
Total Capital
488 589 424 396 492 439 406 374 356 336
Total Debt
0.00 125 0.00 0.00 130 131 132 132 133 133
Total Long-Term Debt
0.00 125 0.00 0.00 127 131 132 132 133 132
Net Debt
-528 -373 -441 -417 -241 -216 -177 -160 -134 -123
Capital Expenditures (CapEx)
5.43 2.54 2.92 3.70 2.78 1.30 1.51 1.73 0.34 0.08
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-48 -46 -29 -36 -26 -24 -18 -28 -23 -36
Debt-free Net Working Capital (DFNWC)
460 452 411 381 345 322 291 263 221 187
Net Working Capital (NWC)
460 452 411 381 342 322 291 263 221 186
Net Nonoperating Expense (NNE)
14 13 18 14 15 20 13 13 9.25 10
Net Nonoperating Obligations (NNO)
-528 -373 -441 -417 -241 -216 -181 -160 -134 -123
Total Depreciation and Amortization (D&A)
5.79 4.20 3.81 3.74 3.07 2.43 2.57 2.90 2.58 2.99
Debt-free, Cash-free Net Working Capital to Revenue
-28.40% -24.74% -15.98% -18.86% -14.47% -14.23% -10.19% -16.86% -12.75% -19.97%
Debt-free Net Working Capital to Revenue
273.96% 244.11% 223.09% 201.20% 192.07% 189.21% 166.81% 156.09% 124.50% 104.25%
Net Working Capital to Revenue
273.96% 244.11% 223.09% 201.20% 190.29% 189.21% 166.81% 156.09% 124.50% 103.77%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.32) ($0.27) ($0.40) ($0.33) ($0.35) ($0.48) ($0.33) ($0.31) ($0.22) ($0.22)
Adjusted Weighted Average Basic Shares Outstanding
142.93M 142.52M 143.51M 144.40M 144.70M 144.38M 145.79M 147.41M 147.52M 147.10M
Adjusted Diluted Earnings per Share
($0.32) ($0.27) ($0.40) ($0.33) ($0.35) ($0.48) ($0.33) ($0.31) ($0.22) ($0.22)
Adjusted Weighted Average Diluted Shares Outstanding
142.93M 142.52M 143.51M 144.40M 144.70M 144.38M 145.79M 147.41M 147.52M 147.10M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
143.01M 143.23M 144.31M 144.65M 144.77M 145.09M 147.37M 147.47M 147.58M 148.58M
Normalized Net Operating Profit after Tax (NOPAT)
-32 -27 -40 -33 -36 -32 -34 -28 -23 -24
Normalized NOPAT Margin
-66.49% -49.69% -106.34% -68.41% -94.07% -69.78% -81.52% -65.01% -49.19% -49.91%
Pre Tax Income Margin
-94.75% -72.77% -153.27% -97.72% -132.72% -151.73% -113.52% -107.08% -69.12% -71.04%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-69.57 -10.93 -16.20 -13.26 -13.95 -23.60 -16.29 -17.55 -11.10 -11.46
NOPAT to Interest Expense
-48.70 -7.65 -11.34 -9.29 -9.77 -16.52 -11.40 -12.29 -7.77 -8.02
EBIT Less CapEx to Interest Expense
-77.89 -11.64 -17.03 -14.29 -14.71 -24.03 -16.80 -18.19 -11.22 -11.49
NOPAT Less CapEx to Interest Expense
-57.02 -8.36 -12.17 -10.31 -10.53 -16.95 -11.91 -12.93 -7.89 -8.05
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Adaptive Biotechnologies' Financials

When does Adaptive Biotechnologies's financial year end?

According to the most recent income statement we have on file, Adaptive Biotechnologies' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Adaptive Biotechnologies' net income changed over the last 7 years?

Adaptive Biotechnologies' net income appears to be on an upward trend, with a most recent value of -$159.60 million in 2024, rising from -$42.83 million in 2017. The previous period was -$225.30 million in 2023.

What is Adaptive Biotechnologies's operating income?
Adaptive Biotechnologies's total operating income in 2024 was -$162.55 million, based on the following breakdown:
  • Total Gross Profit: $106.88 million
  • Total Operating Expenses: $269.43 million
How has Adaptive Biotechnologies revenue changed over the last 7 years?

Over the last 7 years, Adaptive Biotechnologies' total revenue changed from $15.69 million in 2017 to $178.96 million in 2024, a change of 1,040.7%.

How much debt does Adaptive Biotechnologies have?

Adaptive Biotechnologies' total liabilities were at $336.89 million at the end of 2024, a 4.5% decrease from 2023, and a 1,025.1% increase since 2018.

How much cash does Adaptive Biotechnologies have?

In the past 6 years, Adaptive Biotechnologies' cash and equivalents has ranged from $47.92 million in 2024 to $139.07 million in 2021, and is currently $47.92 million as of their latest financial filing in 2024.

How has Adaptive Biotechnologies' book value per share changed over the last 7 years?

Over the last 7 years, Adaptive Biotechnologies' book value per share changed from 0.00 in 2017 to 1.37 in 2024, a change of 137.4%.

Remove Ads


This page (NASDAQ:ADPT) was last updated on 4/16/2025 by MarketBeat.com Staff
From Our Partners